Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

The cyclooxygenase inhibitor sulindac sulfide inhibits EP4 expression and suppresses the growth of glioblastoma cells.

Kambe A, Yoshioka H, Kamitani H, Watanabe T, Baek SJ, Eling TE.

Cancer Prev Res (Phila). 2009 Dec;2(12):1088-99. doi: 10.1158/1940-6207.CAPR-09-0140. Epub 2009 Nov 24.

2.

Regulation of EP4 expression via the Sp-1 transcription factor: inhibition of expression by anti-cancer agents.

Kambe A, Iguchi G, Moon Y, Kamitani H, Watanabe T, Eling TE.

Biochim Biophys Acta. 2008 Jun;1783(6):1211-9. doi: 10.1016/j.bbamcr.2008.01.032. Epub 2008 Feb 20.

3.

Gene modulation by the cyclooxygenase inhibitor, sulindac sulfide, in human colorectal carcinoma cells: possible link to apoptosis.

Bottone FG Jr, Martinez JM, Collins JB, Afshari CA, Eling TE.

J Biol Chem. 2003 Jul 11;278(28):25790-801. Epub 2003 May 6.

4.

Transcriptional regulation of activating transcription factor 3 involves the early growth response-1 gene.

Bottone FG Jr, Moon Y, Alston-Mills B, Eling TE.

J Pharmacol Exp Ther. 2005 Nov;315(2):668-77. Epub 2005 Aug 3.

5.
7.
8.
9.

Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells.

Rice PL, Washington M, Schleman S, Beard KS, Driggers LJ, Ahnen DJ.

Cancer Res. 2003 Feb 1;63(3):616-20.

10.

Prostaglandin E2 stimulates human lung carcinoma cell growth through induction of integrin-linked kinase: the involvement of EP4 and Sp1.

Zheng Y, Ritzenthaler JD, Sun X, Roman J, Han S.

Cancer Res. 2009 Feb 1;69(3):896-904. doi: 10.1158/0008-5472.CAN-08-2677. Epub 2009 Jan 27.

12.

The induction of S100p expression by the Prostaglandin E₂ (PGE₂)/EP4 receptor signaling pathway in colon cancer cells.

Chandramouli A, Mercado-Pimentel ME, Hutchinson A, Gibadulinová A, Olson ER, Dickinson S, Shañas R, Davenport J, Owens J, Bhattacharyya AK, Regan JW, Pastorekova S, Arumugam T, Logsdon CD, Nelson MA.

Cancer Biol Ther. 2010 Nov 15;10(10):1056-66. doi: 10.4161/cbt.10.10.13373. Epub 2010 Nov 15.

13.

Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites.

Rice PL, Goldberg RJ, Ray EC, Driggers LJ, Ahnen DJ.

Cancer Res. 2001 Feb 15;61(4):1541-7.

14.

Nonsteroidal anti-inflammatory drug sulindac sulfide suppresses structural protein Nesprin-2 expression in colorectal cancer cells.

Liggett JL, Choi CK, Donnell RL, Kihm KD, Kim JS, Min KW, Noegel AA, Baek SJ.

Biochim Biophys Acta. 2014 Jan;1840(1):322-31. doi: 10.1016/j.bbagen.2013.09.032. Epub 2013 Sep 27.

16.

The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3).

Bottone FG Jr, Moon Y, Kim JS, Alston-Mills B, Ishibashi M, Eling TE.

Mol Cancer Ther. 2005 May;4(5):693-703.

17.

The cyclooxygenase inhibitor indomethacin modulates gene expression and represses the extracellular matrix protein laminin gamma1 in human glioblastoma cells.

Ishibashi M, Bottone FG Jr, Taniura S, Kamitani H, Watanabe T, Eling TE.

Exp Cell Res. 2005 Jan 15;302(2):244-52.

PMID:
15561105
18.

PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells.

Nikitakis NG, Hebert C, Lopes MA, Reynolds MA, Sauk JJ.

Int J Cancer. 2002 Apr 20;98(6):817-23.

20.

Sulindac sulfide-induced apoptosis in sinonasal cancer cells.

Kim CH, Song KS, Kim KS, Kim JY, Lee BJ, Lee JG, Yoon JH.

Acta Otolaryngol. 2005 Feb;125(2):201-6.

PMID:
15880954
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk